Burosumab: 13 agencies, 2017–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 8.6 years, from 28 Dec 2017 at AWMSG (Wales) to 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 15 of 34 records date from 2023 or later.
7 distinct indication wordings are recorded for burosumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 34 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess burosumab, on 28 Dec 2017; NICE (England) did not open a file until 7 Aug 2024 — a wide spread of 6.7 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 8 years in total.
11 of the 13 agencies here assessed burosumab more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
burosumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for burosumab reads 13 recommended, 9 not recommended, 4 restricted and 3 other, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 30 Oct 2025 | programu lekowego B.151 „Leczenie chorych na hipofosfatemię sprzężoną z chromosomem X (XLH) (ICD-10: E.83.3) | recommended conditionally | source |
| CONITEC (Brazil) | 29 May 2025 | Tratamento da hipofosfatemia ligada ao cromossomo X (HLX) em pacientes adultos (idade igual ou superior a 18 anos). | not incorporated | source |
| CIPM (Spain) | 23 Oct 2024 | Indicaciones terapéuticas autorizadas: CRYSVITA está indicado para el tratamiento de la hipofosfatemia ligada al cromoso… | financed by the SNS · art. 92 a, c, d | source |
| NYE METODER (Norway) | 25 Aug 2024 | Behandling av FGF23-relatert hypofosfatemi hos pasienter ≥1 år med tumorindusert osteomalasi (TIO) assosiert med fosfata… | decision recorded | source |
| NICE (England) | 7 Aug 2024 | NICE TA993 | recommended (optimised) | source |
29 further decisions for burosumab, across 12 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- denosumab — same ATC class M05B — Bone diseases
- romosozumab — same ATC class M05B — Bone diseases
- zoledronic acid — same ATC class M05B — Bone diseases
- vosoritide — same ATC class M05B — Bone diseases
- dibotermin alfa — same ATC class M05B — Bone diseases
- ibandronic acid — same ATC class M05B — Bone diseases
Coverage: 34 decisions for burosumab from 13 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class M05B — Bone diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.